Accuray (ARAY) Given Daily Media Sentiment Score of 0.31
Media coverage about Accuray (NASDAQ:ARAY) has trended positive recently, according to Accern. The research group scores the sentiment of press coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Accuray earned a coverage optimism score of 0.31 on Accern’s scale. Accern also assigned press coverage about the medical equipment provider an impact score of 45.5693671472389 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Company Watch: Stock Nearing 52-Week Low Accuray Incorporated (NASDAQ:ARAY) – Sparta Review (spartareview.com)
- Accuray Incorporated (NASDAQ:ARAY) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- The Bear Case for Accuray Incorporated (ARAY) – Economic News (economicsandmoney.com)
- Accuray Incorporated (NASDAQ:ARAY) Receives Buy Rating from Jefferies Group LLC (americanbankingnews.com)
- Accuray Incorporated (ARAY) noted a price change of -6.82% and Retrophin, Inc. (RTRX) closes with a move of -0.62% – Stocks Gallery (stocksgallery.com)
Accuray (ARAY) traded down 2.44% during midday trading on Friday, reaching $4.00. 264,844 shares of the company were exchanged. The company’s market capitalization is $332.00 million. The company has a 50 day moving average of $4.47 and a 200-day moving average of $4.69. Accuray has a 52-week low of $3.85 and a 52-week high of $6.39.
ARAY has been the subject of several recent research reports. BidaskClub lowered shares of Accuray from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Zacks Investment Research cut shares of Accuray from a “hold” rating to a “strong sell” rating in a research note on Monday, July 24th. Jefferies Group LLC reissued a “buy” rating and issued a $7.00 price target on shares of Accuray in a research note on Friday, June 30th. Finally, BTIG Research reissued a “hold” rating on shares of Accuray in a research note on Sunday, April 30th. Two analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Hold” and a consensus price target of $7.04.
Accuray Company Profile
Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.
Receive News & Ratings for Accuray Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.